2587 results about "Immunologic function" patented technology

This invention describes methods of using anti-B cell antibodies, preferably anti-CD20 antibodies, and most preferably Rituximab, to treat B cell lymphomas of the brain, especially primary central nervous system lymphomas (PCNSLs), and to prevent meningeal relapse. The antibodies can be administered intrathecally alone, or in combination with other chemotherapeutics, such as methotrexate, or other anti-B cell antibodies to treat PCNSL in both immunocompromised and non-immunocompromised patients. These antibodies can also be used to diagnose patients with CNS lymphoma, especially in immunocompromised patients.

A device and method for treatment of impairments relating to neuropathy rely on sensory substitution to train a patient to associate an affected condition with stimuli that are generated based on detection of the condition.

The present invention relates to a process for producing a desired polypeptide using rat cells. Specifically, the present invention relates to a process for producing the polypeptide which comprises culturing rat cells such as YB2 / 3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2 / 0), preferably rat cells to which a recombinant DNA comprising DNA encoding a desired polypeptide such as an immunologically functional molecule is introduced, in a medium which does not contain serum (hereinafter referred to as a serum-free medium). Among the desired polypeptides obtained by the process of the present invention, an antibody obtained by using a transformant of YB2 / 0 has a high antibody-dependent cell-mediated cytotoxic activity (hereinafter sometimes referred to as ADCC activity) and is useful as a pharmaceutical agent.

The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases including bone disorders, inflammatory diseases, neurological diseases, ocular diseases, renal diseases, pulmonary diseases and skin diseases are also disclosed.

The present invention concerns methods and compositions for subunit-based vaccines for inducing immunity against poxvirus infections, such as smallpox. Preferred embodiments concern immunoconjugates comprising one or more subunit antigenic peptides attached to an antibody or fragment thereof that targets antigen-producing cells (APCs). More preferably, the antibody binds to HLA-DR and the antigenic peptide is from an immunomodulating factor, such as the viral IL-18 binding protein (vIL18BP). However, mixtures of antigenic peptides from different viral proteins may also be used. The vaccine is capable of inducing immunity against poxvirus without risk of disseminated infection in immunocompromised hosts or transmission to susceptible contacts.

The invention provides a curcumin oral emulsion and injection, wherein the emulsion comprises curcumin, oil, emulsifying agent and water, the injection also contains isotonic agent. The invention also discloses the process for preparing the emulsion and its use in preparing medicaments for treating or preventing tumor, resisting tumor transfer, enhancing curative effects of chemotherapy drugs, reducing side effects of chemotherapy and improving immunity functions for tumor patients.

The invention relates to the field of immunology. Specifically, the invention relates to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease or inflammatory disease. The invention provides for an immunoregulator (IR), use of an IR in preparing a pharmaceutical composition for treating an immune-mediated disorder and a method for treating an immune-mediated disorder.

The present invention relates to molecules that stabilize and / or enhance CD154 activity, compositions comprising these molecules, methods for using these molecules and compositions (e.g., pharmaceutical compositions) comprising them. Specifically, the molecules can be used for enhancing immune function (e.g., enhancing Th1 cytokine expression), stimulating immune responses, and / or treating certain disorders (e.g., cancer, infectious disease, and immune compromised states). The invention also relates to kits and compositions comprising the molecules.

The present invention belongs to the fields of molecular biology and immunology and relates to a chimeric antigen receptor combining EGFR (epidermal growth factor receptor) family proteins and a composition and uses thereof The present invention particularly relates to the chimeric antigen receptor comprising polypeptides efficiently combining the EGFR family proteins and transmembrane domains, wherein the polypeptides efficiently combining EGFR family proteins comprise HERIN. The chimeric antigen receptor can promote the proliferation ability and killing effect of T cell at the premise of maintaining the killing specificity of the T cell.

The present invention concerns CAR, CAR-T and CAR-NK constructs, preferably comprising a scFv antibody fragment against a disease-associated antigen or a hapten. More preferably, the antigen is a TAA, such as Trop-2. The constructs may be administered to a subject with a disease, such as cancer, autoimmune disease, or immune dysfunction disease, to induce an immune response against disease-associated cells. Where the constructs bind to a hapten, the subject is first treated with a hapten-conjugated antibody that binds to a disease associated antigen. Therapy may be supplemented by other treatments, such as debulking procedures (e.g., surgery, chemotherapy, radiation therapy) or coadministration of other agents. More preferably, administration of the construct is preceded by predosing with an unconjugated antibody that binds to the same disease-associated antigen. Most preferably, an antibody against CD74 or HLA-DR is administered to reduce systemic immunotoxicity induced by the constructs.

This invention relates to polysaccharides extract from Dendrobium candidum and its preparation method. The molecular weight of the polysaccharide extract of Dendrobium candidum is 10000-300000. The content of polysaccharide is no less than 25 wt%. The invention also relates to a Chinese medicinal composition containing polysaccharide extract from Dendrobium candidum and its preparation method, and application of the polysaccharide extract in preparing medicine for auxiliary treatment of diseases caused by hypoimmunity. The extract and Chinese medicinal composition containing the same can improve immunologic function with high bioavailability, no toxicity and adverse side effect. the preparation method is simple and convenient for operation and commercial process.

Human breast tumors contain hetrogeneous cancer cells. using an animal xenograft model in which human breast cancer cells were grown in immunocompromised mice we found that only a small minority of breast cancer cells had capacity to form new tumors. The ability to form new tumors was not a slochastic property, rather certain populations of cancer cells were depleted for the ability to form new tumors, while other populations were enriched for the ability to form new tumors. Tumorigenic cells could be distinguished from non-tumorigenic cancer cells based on surface marker expression. We prospectively identified and isolated the tumorigenic cells as CD4430CD24− / lowLINEAGE A few as 100 cells from this population were able to form tumors the animal xenograft model, while tens of thousands of cells from non-tumorigenic populations failed to form tumors. The tumorigenic cells could be serially passaged, each time generating new tumors containing and expanded numbers of CD44+CD24 Lineage tumorigenic cells as well as phenotypically mixed populations of non-tumorigenic cancer cells. This is reminiscent of the ability of normal stem cells to self-renew and differentiate. The expression of potential therapeutic targets also differed between the tumorigenic and non-tumorigenic populations. Notch activation promoted the survival of the tumorigenic cells, and a blocking antibody against Notch 4 induced tumorigenic breast cancer cells to undergo apoptosis.

The present invention relates to feed additives for cats. The invention provides methods for making a biological compositions comprising yeast cells that can improve the immune functions of cats. The invention also relates to methods for manufacturing the biological compositions, and methods of using the biological compositions as feed additives.

The invention relates to a prebiotic peptide biological feed additive and a preparation method and application thereof. The prebiotic peptide biological feed additive is prepared by mixing and fermentation of seed solution with one or more of bacillus, yeast and lactic acid bacteria in plant protease hydrolysate. After animal and plant protein is subjected to enzymolysis at constant or changeable temperature, the seed solution with one or more of bacillus, yeast and lactic acid bacteria is added for fermentation according to a certain proportion, and the fermented solution is concentrated and dried to obtain a powdery product. The problems of high content of bitter peptides and poor palatability of enzymolysis processes using acid, alkali and protease can be solved. The immune function of animals can be stimulated by active peptides in the prebiotic peptide biological feed additive, the immunity of the animals can be improved, the intestinal environment of the animals can be improved by probiotics, the resistance of the animals to a variety of diseases can be enhanced, the feed conversion rate can be increased, and the breeding cost can be reduced.

According to the present invention, there are provided a method for producing a human T cell, which comprises the steps of inducing an iPS cell from a human T cell, and differentiating the iPS cell into a T cell; a pharmaceutical composition comprising the T cell produced by the method; and a method for cell-based immunotherapy using the method.

The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease and other inflammatory diseases. The invention in particular relates to the systemic treatment of inflammatory disease by oral or mucosal administration of a pharmaceutical composition with a gene-regulatory peptide. The invention provides a pharmaceutical composition in a form for mucosal application for the treatment of a subject suffering from disease, the pharmaceutical composition comprising a pharmacologically effective amount of a gene-regulatory peptide or a functional analogue thereof together with a pharmaceutically acceptable diluent.

The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by influenza virus. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.

Presented herein are therapeutic agents that modulate one or more immune functions and uses of such therapeutic agents in the prevention, treatment and management of diseases. In one aspect, the therapeutic agents modulate one or more signal transduction pathways induced by the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. In another aspect, the therapeutic agents modulate the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. The therapeutic agents can be used in the prevention, treatment and / or management of diseases in which it might be useful to modulate one or more immune functions (e.g., cancer, infectious disease, autoimmune disease, and transplantation rejection). In another aspect, presented herein are methods for identifying receptor-ligand interactions.

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.

The present invention is related to the fields of vaccinology, immunology and medicine. The invention provides compositions and methods for enhancing immunological responses against antigens coupled or fused to virus-like particles (VLPs) packaged with immunostimulatory nucleic acids, preferably oligonucleotides containing at least one non-methylated CpG sequence and a toll-like receptor (TLR) ligand. The invention can be used to induce strong antibody and T cell responses particularly useful for the treatment of allergies, tumors and chronic viral diseases as well as other chronic diseases.

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor CXCR5. The CXCR5 receptor compounds are derived from the intracellular loops and domains of the CXCR5 receptor. The invention also relates to the use of these CXCR5 receptor compounds and pharmaceutical compositions comprising the CXCR5 receptor compounds in the treatment of diseases and conditions associated with CXCR5 receptor modulation such as autoimmune diseases including lupus, HIV and rheumatoid arthritis, Primary Sjogren's Syndrome, chronic lymphocytic leukemia, Burkitt Lymphoma, colon and breast cancer tumor metastasis, Multiple Sclerosis and compromised immune function.

The present invention relates to medicine and veterinary, namely, to immunology, and to methods aimed at correcting the immune system of a living organism. The essence of the invention is in the immunocorrection of the organism using pharmacologically appropriate amino derivatives of 2,3-dihydrophthalazine-1,4~dione in their effective doses ranging from 0.2 mug to 1,000 mg.

The invention belongs to the fields of immunology and cytobiology and relates to a molecular brake for rapidly stopping the killing effect of CAR-T (T cell engineered with chimeric antigen receptors) and an application of the molecular brake. Specifically, the molecular brake serving as an element is inserted into the specific position in the CAR and can rapidly stop the killing effect of the CAR-T on a target cell, thereby effectively improving the safety of CAR-T treatment. The invention further relates to immunoreactive cells expressing the CAR and an application of the immunoreactive cells in preparation of drugs for treating malignant tumors or virus infectious diseases.

Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.

The invention discloses an anti-stress anti-diarrhea growth-promotion Chinese herbal medicine feed additive for a weaned pig, which is obtained by carrying out the superfine grinding and mixing on the following components at the mass ratio: 1-5 parts of Astragalus mongholicus, 1 part of Scutellaria baicalensis, 1 part of malt, 1 part of liquorice, 1-5 parts of dangshen, 1-5 parts of poria cocos and 1-5 parts of largehead atractylodes rhizome. According to the Chinese herbal medicine feed additive disclosed by the invention, the weaned pig growth performance can be improved, and the Chinese herbal medicine feed additive has the anti-diarrhea effect; the gastrointestinal tract development of the weaned pig can be promoted; the activity of the digestive enzyme of the gastrointestinal digestive tract of the wigged pig can be improved to promote the development of the pig digestive enzyme system; the micro-ecological environment of the digestive tract of the pig can be regulated and stabilized to accelerate the pig to grow; the antioxidation function of the wigged pig organism can be improved so as to improve the compensatory capability of the wigged pig organism on external irradiation; the intestinal mucosa form of the wigged pig can be improved so as to alleviate the intestinal villus withering of the wigged pig and promote the tract of the wigged pig to restore; and the immunologic function of the intestinal mucosa of the wigged pig can be regulated.

The invention discloses a healthcare food capable of strengthening immunity. The healthcare food comprises, by weight percentage, 1% to 50% of soybean peptide, 0.5% to 30% of protein powder, 1% to 30% of fructo-oligosaccharide, 0.1% to 30% of coix seed powder, 0.1% to 10% of spirulina and 15% to 85% of auxiliary materials. According to the healthcare food, materials which are nutritious and effective are selected to be subjected to scientific formulating prescription, nutrition, safety, palatability and efficacy are taken as principles, and effects of strengthening cell immune function and humoral immune function are achieved, thereby immunity strengthening is achieved.

The invention discloses a novel traditional Chinese medicine composition for treating the fatigue syndrome of sub-healthy people and the fatigue, the hypodynamia and the inferior immunologic function of a patient with acquired immune deficiency syndrome and a preparation method thereof. The main components of the traditional Chinese medicine composition comprise the following several raw materials of medicines: crude astragalus root, yam, white peony root, radix codonopsis pilosulae, angelica, solomonseal, ginseng, tuber fleeceflower, American ginseng, antler, aweto, ophiopogon root, Chinese wolfberry and prepared rehmannia root. The medicine composition can be prepared into any common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can obviously improve sub-health, fatigue syndrome, fatigue and hypodynamia of patients with acquired immune deficiency syndrome, enhances the self immunity and has the advantages of definite curative effect, obvious effect, convenient taking, quick acting, wide suitable crowd, no toxic or side effect and the like.

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an Aβ1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one Aβ1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.